- Home
- Publications
- Publication Search
- Publication Details
Title
Romosozumab in the treatment of osteoporosis
Authors
Keywords
-
Journal
Immunotherapy
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2020-08-05
DOI
10.2217/imt-2020-0158
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
- (2020) Emil H. Schemitsch et al. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
- Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate
- (2019) Kamyar Asadipooya et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
- (2019) Pascale Chavassieux et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone–Vascular Axis
- (2019) Annelies De Maré et al. Toxins
- Standard vs Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial
- (2019) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
- (2019) Ian R Reid et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
- (2019) D.L. Kendler et al. OSTEOPOROSIS INTERNATIONAL
- Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
- (2019) J. A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
- (2019) Fang Lv et al. BONE
- Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials
- (2018) Y. Liu et al. CLIMACTERIC
- Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
- (2018) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
- (2018) Michael R McClung et al. JOURNAL OF BONE AND MINERAL RESEARCH
- FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
- (2018) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- A Phase 3 Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
- (2018) E Michael Lewiecki et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The underlying pathophysiology and therapeutic approaches for osteoporosis
- (2018) Harshika Awasthi et al. MEDICINAL RESEARCH REVIEWS
- Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models
- (2018) Aimy Sebastian et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
- (2018) E Michael Lewiecki et al. JOURNAL OF BONE AND MINERAL RESEARCH
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women
- (2018) J.A. Kanis et al. OSTEOPOROSIS INTERNATIONAL
- Novel actions of sclerostin on bone
- (2018) Gill Holdsworth et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass
- (2017) Tony M Keaveny et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
- (2017) Bente L Langdahl et al. LANCET
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
- (2016) Guido Kranenburg et al. ATHEROSCLEROSIS
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016
- (2016) Pauline M. Camacho et al. Endocrine Practice
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
- (2016) Paul D. Miller et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study
- (2016) Luc Chouinard et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Postmenopausal osteoporosis
- (2016) Richard Eastell et al. Nature Reviews Disease Primers
- Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis
- (2015) Christian Graeff et al. BONE
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- (2015) Benjamin Z Leder et al. LANCET
- Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
- (2015) Ove Törring Therapeutic Advances in Musculoskeletal Disease
- Biological agents in management of osteoporosis
- (2014) Sri Harsha Tella et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
- (2014) Benjamin Z. Leder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density
- (2014) Michael R. McClung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tissue-Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody
- (2013) Michael S Ominsky et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study
- (2013) Desmond Padhi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
- (2013) Ernesto Canalis Nature Reviews Endocrinology
- Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
- (2012) Hua Zhu Ke et al. ENDOCRINE REVIEWS
- Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis
- (2012) Mohammad Hassan Murad et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Patients with sclerosteosis and disease carriers: Human models of the effect of sclerostin on bone turnover
- (2011) Antoon H van Lierop et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Osteoporosis: now and the future
- (2011) Tilman D Rachner et al. LANCET
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
- (2010) A. Papaioannou et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength
- (2010) Michael S Ominsky et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
- (2010) Desmond Padhi et al. JOURNAL OF BONE AND MINERAL RESEARCH
- A Short Treatment With an Antibody to Sclerostin Can Inhibit Bone Loss in an Ongoing Model of Colitis*
- (2009) Alison Eddleston et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength
- (2008) Xiaodong Li et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis*
- (2008) Xiaodong Li et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate
- (2008) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis
- (2007) Steven Boonen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started